Laman UtamaA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Tutup sebelumnya
R$71.74
Julat tahun
R$36.23 - R$85.44
Permodalan pasaran
31.36B USD
Bilangan Purata
38.00
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 593.17J | 34.90% |
Perbelanjaan pengendalian | 595.51J | 26.63% |
Pendapatan bersih | -83.76J | 39.24% |
Margin untung bersih | -14.12 | 54.96% |
Pendapatan bagi setiap syer | 0.06 | 107.79% |
EBITDA | -90.99J | 11.59% |
Kadar cukai berkesan | 56.81% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 2.69B | 10.46% |
Jumlah aset | 4.24B | 10.71% |
Jumlah liabiliti | 4.17B | 3.02% |
Jumlah ekuiti | 67.09J | — |
Syer tertunggak | 129.46J | — |
Harga kepada buku | 137.96 | — |
Pulangan pada aset | -6.23% | — |
Pulangan pada modal | -9.44% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -83.76J | 39.24% |
Tunai daripada operasi | -94.66J | -217.71% |
Tunai daripada pelaburan | -52.91J | 78.01% |
Tunai daripada pembiayaan | 31.00J | -20.98% |
Perubahan bersih dalam tunai | -133.85J | 39.25% |
Aliran tunai bebas | -110.30J | -165.23% |
Perihal
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Diasaskan
14 Jun 2002
Tapak web
Pekerja
2,230
